Vita Life Sciences Ltd (VLS) - Net Assets

Latest as of June 2025: AU$52.62 Million AUD ≈ $37.23 Million USD

Based on the latest financial reports, Vita Life Sciences Ltd (VLS) has net assets worth AU$52.62 Million AUD (≈ $37.23 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$74.64 Million ≈ $52.82 Million USD) and total liabilities (AU$22.03 Million ≈ $15.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vita Life Sciences Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$52.62 Million
% of Total Assets	70.49%
Annual Growth Rate	2.49%
5-Year Change	113.9%
10-Year Change	128.55%
Growth Volatility	49.99

Vita Life Sciences Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Vita Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore VLS total asset value for the complete picture of this company's asset base.

Annual Net Assets for Vita Life Sciences Ltd (2000–2024)

The table below shows the annual net assets of Vita Life Sciences Ltd from 2000 to 2024. For live valuation and market cap data, see how much is Vita Life Sciences Ltd worth.

Year	Net Assets	Change
2024-12-31	AU$52.28 Million ≈ $36.99 Million	+20.66%
2023-12-31	AU$43.33 Million ≈ $30.66 Million	+18.71%
2022-12-31	AU$36.50 Million ≈ $25.83 Million	+19.98%
2021-12-31	AU$30.42 Million ≈ $21.53 Million	+24.47%
2020-12-31	AU$24.44 Million ≈ $17.29 Million	+8.47%
2019-12-31	AU$22.53 Million ≈ $15.94 Million	+0.57%
2018-12-31	AU$22.41 Million ≈ $15.85 Million	-9.62%
2017-12-31	AU$24.79 Million ≈ $17.54 Million	+6.98%
2016-12-31	AU$23.18 Million ≈ $16.40 Million	+1.31%
2015-12-31	AU$22.88 Million ≈ $16.19 Million	+6.08%
2014-12-31	AU$21.57 Million ≈ $15.26 Million	+32.55%
2013-12-31	AU$16.27 Million ≈ $11.51 Million	+43.44%
2012-12-31	AU$11.34 Million ≈ $8.03 Million	+26.64%
2011-12-31	AU$8.96 Million ≈ $6.34 Million	+10.16%
2010-12-31	AU$8.13 Million ≈ $5.75 Million	+108.41%
2009-12-31	AU$3.90 Million ≈ $2.76 Million	+1.44%
2008-12-31	AU$3.85 Million ≈ $2.72 Million	+33.54%
2007-12-31	AU$2.88 Million ≈ $2.04 Million	-13.97%
2006-12-31	AU$3.35 Million ≈ $2.37 Million	+124.29%
2005-12-31	AU$-13.78 Million ≈ $-9.75 Million	-35.19%
2004-12-31	AU$-10.20 Million ≈ $-7.21 Million	-9.31%
2003-12-31	AU$-9.33 Million ≈ $-6.60 Million	-169.31%
2002-12-31	AU$13.46 Million ≈ $9.52 Million	-66.51%
2001-12-31	AU$40.18 Million ≈ $28.43 Million	+38.83%
2000-12-31	AU$28.94 Million ≈ $20.48 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Vita Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 71.1% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	AU$846.00K	1.62%
Common Stock	AU$45.03 Million	86.01%
Other Comprehensive Income	AU$6.48 Million	12.38%
Total Equity	AU$52.35 Million	100.00%

Vita Life Sciences Ltd Competitors by Market Cap

The table below lists competitors of Vita Life Sciences Ltd ranked by their market capitalization.

Company	Market Cap
NCS Multistage Holdings Inc NASDAQ:NCSM	$98.18 Million
Genovate Biotechnology Co Ltd TWO:4130	$98.20 Million
Papaya Growth Opportunity Corp I NASDAQ:PPYA	$98.24 Million
Ablerex Electronics Co Ltd TWO:3628	$98.25 Million
Dhunseri Ventures Limited NSE:DVL	$98.16 Million
Pinar Sut Mamulleri Sanayi AS IS:PNSUT	$98.10 Million
Miwon Holdings Co. Ltd KO:107590	$98.07 Million
Bioton S.A. WAR:BIO	$98.07 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vita Life Sciences Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 43,397,000 to 52,354,000, a change of 8,957,000 (20.6%).
Net income of 8,784,000 contributed positively to equity growth.
Dividend payments of 5,169,000 reduced retained earnings.
Share repurchases of 1,393,000 reduced equity.
New share issuances of 3,856,000 increased equity.
Other comprehensive income increased equity by 2,880,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	AU$8.78 Million	+16.78%
Dividends Paid	AU$5.17 Million	-9.87%
Share Repurchases	AU$1.39 Million	-2.66%
Share Issuances	AU$3.86 Million	+7.37%
Other Comprehensive Income	AU$2.88 Million	+5.5%
Other Changes	AU$-1.00K	-0.0%
Total Change	AU$-	20.64%

Book Value vs Market Value Analysis

This analysis compares Vita Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.67x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 27.84x to 2.67x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	AU$0.09	AU$2.54	x
2008-12-31	AU$0.07	AU$2.54	x
2009-12-31	AU$0.07	AU$2.54	x
2010-12-31	AU$0.14	AU$2.54	x
2011-12-31	AU$0.15	AU$2.54	x
2012-12-31	AU$0.20	AU$2.54	x
2013-12-31	AU$0.29	AU$2.54	x
2014-12-31	AU$0.38	AU$2.54	x
2015-12-31	AU$0.40	AU$2.54	x
2016-12-31	AU$0.41	AU$2.54	x
2017-12-31	AU$0.45	AU$2.54	x
2018-12-31	AU$0.41	AU$2.54	x
2019-12-31	AU$0.41	AU$2.54	x
2020-12-31	AU$0.47	AU$2.54	x
2021-12-31	AU$0.58	AU$2.54	x
2022-12-31	AU$0.68	AU$2.54	x
2023-12-31	AU$0.79	AU$2.54	x
2024-12-31	AU$0.95	AU$2.54	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vita Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 16.78%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 11.05%
• Asset Turnover: 1.11x
• Equity Multiplier: 1.37x
Recent ROE (16.78%) is below the historical average (32.40%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2000	18.13%	13.87%	0.77x	1.69x	AU$2.35 Million
2001	0.42%	0.43%	0.59x	1.64x	AU$-3.85 Million
2006	335.51%	88.08%	0.88x	4.35x	AU$9.51 Million
2007	-10.55%	-2.13%	1.76x	2.80x	AU$-493.67K
2008	10.97%	2.46%	1.66x	2.68x	AU$31.19K
2009	-9.62%	-1.93%	1.93x	2.58x	AU$-669.30K
2010	58.28%	22.09%	1.39x	1.90x	AU$3.69 Million
2011	14.28%	5.00%	1.82x	1.57x	AU$363.40K
2012	21.03%	7.84%	1.80x	1.49x	AU$1.24 Million
2013	29.35%	13.41%	1.61x	1.36x	AU$3.13 Million
2014	33.91%	19.90%	1.21x	1.41x	AU$5.13 Million
2015	19.24%	11.38%	1.19x	1.42x	AU$2.11 Million
2016	14.45%	8.83%	1.17x	1.40x	AU$1.03 Million
2017	11.56%	7.59%	1.15x	1.33x	AU$387.20K
2018	10.90%	5.93%	1.15x	1.60x	AU$201.50K
2019	13.88%	7.39%	1.16x	1.62x	AU$876.10K
2020	24.65%	13.11%	1.19x	1.58x	AU$3.62 Million
2021	26.96%	14.52%	1.26x	1.47x	AU$5.22 Million
2022	19.37%	10.59%	1.29x	1.42x	AU$3.43 Million
2023	20.92%	12.24%	1.24x	1.38x	AU$4.74 Million
2024	16.78%	11.05%	1.11x	1.37x	AU$3.55 Million

Industry Comparison

This section compares Vita Life Sciences Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $29,670,098
Average return on equity (ROE) among peers: 4903.30%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Vita Life Sciences Ltd (VLS)	AU$52.62 Million	18.13%	0.42x	$98.16 Million
Althea Group Holdings Ltd (AGH)	$41.45 Million	-29.25%	0.36x	$12.05 Million
BOD Science Ltd (BOD)	$3.47 Million	-155.95%	0.53x	$3.01 Million
BPH Global Ltd (BP8)	$149.84K	50079.24%	22.90x	$2.62 Million
Cann Group Ltd (CAN)	$648.33K	-644.19%	0.12x	$5.62 Million
ECS Botanics Holdings Ltd (ECS)	$319.74K	-109.87%	0.16x	$5.65 Million
Ecofibre Ltd (EOF)	$109.94 Million	-13.34%	0.36x	$5.36 Million
Epsilon Healthcare Ltd (EPN)	$2.99 Million	-68.61%	4.98x	$5.51 Million
Elixinol Wellness Ltd (EXL)	$99.42 Million	0.00%	0.04x	$2.05 Million
IDT Australia Ltd (IDT)	$32.86 Million	21.64%	0.29x	$12.10 Million
Invion Ltd (IVX)	$5.46 Million	-46.66%	0.11x	$3.70 Million

About Vita Life Sciences Ltd

AU:VLS Australia Drug Manufacturers - Specialty & Generic

Market Cap

$98.16 Million

AU$138.74 Million AUD

Market Cap Rank

#19259 Global

#630 in Australia

Share Price

AU$2.54

Change (1 day)

-0.39%

52-Week Range

AU$1.76 - AU$2.83

All Time High

AU$2.83